Predicted to enable complement component C3b binding activity and heparin binding activity. Predicted to be involved in complement activation. Predicted to be located in extracellular region. Predicted to be active in extracellular space. Orthologous to human CFHR4 (complement factor H related 4); INTERACTS WITH (+)-schisandrin B; 17beta-estradiol; acetamide.
complement factor H-related protein; complement factor H-related protein-like; LOC498241; RGD1564614; similar to complement component factor H; similar to complement factor H-related protein
[6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with more ...
[6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with more ...
[6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with more ...
[6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with more ...
[6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with more ...
[6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with more ...